126 related articles for article (PubMed ID: 34497196)
1. [B cell acute lymphoblastic leukemia therapy: an up to date overview].
Hayakawa F
Rinsho Ketsueki; 2021; 62(8):1094-1101. PubMed ID: 34497196
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
4. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia.
McCall D; Jabbour E; Roth M; Nunez C; Cuglievan B
Pediatr Blood Cancer; 2023 Jan; 70(1):e29939. PubMed ID: 36031729
[TBL] [Abstract][Full Text] [Related]
5. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
Dhakal P; Kaur J; Gundabolu K; Bhatt VR
Leuk Lymphoma; 2020 Jan; 61(1):7-17. PubMed ID: 31317803
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
9. [Antibody therapy for acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
Fuster JL; Molinos-Quintana A; Fuentes C; Fernández JM; Velasco P; Pascual T; Rives S; Dapena JL; Sisinni L; López-Godino O; Palomo P; Villa-Alcázar M; Bautista F; González-Vicent M; López-Duarte M; García-Morín M; Ramos-Elbal E; Ramírez M;
Br J Haematol; 2020 Sep; 190(5):764-771. PubMed ID: 32314348
[TBL] [Abstract][Full Text] [Related]
11. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
[TBL] [Abstract][Full Text] [Related]
12. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
13. [Adult acute lymphoblastic leukemia: update on pathophysiology and management].
Hayakawa F
Rinsho Ketsueki; 2018; 59(5):497-503. PubMed ID: 29877239
[TBL] [Abstract][Full Text] [Related]
14. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
15. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B
Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837
[No Abstract] [Full Text] [Related]
16. Current Management and New Developments in the Treatment of ALL.
Darrah J; Sun W
Cancer Treat Res; 2021; 181():75-96. PubMed ID: 34626356
[TBL] [Abstract][Full Text] [Related]
17. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
18. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
Tvito A; Rowe JM
Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
[TBL] [Abstract][Full Text] [Related]
20. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]